Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome

Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease with high prevalence and possible poor prognosis. Though the pathogenesis of pSS has not been fully elucidated, B cell hyperactivity is considered as one of the fundamental abnormalities in pSS patients. It has long been identifi...

Full description

Saved in:
Bibliographic Details
Published inChinese medical journal Vol. 136; no. 19; pp. 2297 - 2306
Main Authors Li, Mucong, Li, Mengtao, Qiao, Lin, Wu, Chanyuan, Xu, Dong, Zhao, Yan, Zeng, Xiaofeng
Format Journal Article
LanguageEnglish
Published China Lippincott Williams & Wilkins 05.10.2023
Lippincott Williams & Wilkins Ovid Technologies
Wolters Kluwer
Subjects
Apoptosis
Arthritis
Autoimmune diseases
Cells
Cytokines
Deoxyribonucleic acid
DNA
Drugs
Epigenetics
Exocrine glands
Genes
Granulocytes
Humans
Immune system
Janus Kinases - metabolism
Kinases
Lymphocytes
Lymphoma
Nervous system
Pathogenesis
Proteins
Review
Ribonucleic acid
RNA
Signal Transduction
Sjogren's Syndrome - drug therapy
Sjogren's Syndrome - metabolism
Skin diseases
STAT Transcription Factors - metabolism
STAT1 Transcription Factor - metabolism
STAT3 Transcription Factor - metabolism
Tumor necrosis factor-TNF
Online AccessGet full text

Cover

More Information
Summary:Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease with high prevalence and possible poor prognosis. Though the pathogenesis of pSS has not been fully elucidated, B cell hyperactivity is considered as one of the fundamental abnormalities in pSS patients. It has long been identified that Janus kinases-signal transducer and activator of transcription (JAK-STAT) signaling pathway contributes to rheumatoid arthritis and systemic lupus erythematosus. Recently, increasing numbers of studies have provided evidence that JAK-STAT pathway also has an important role in the pathogenesis of pSS via direct or indirect activation of B cells. Signal transducer and activator of transcription 1 (STAT1), STAT3, and STAT5 activated by various cytokines and ribonucleic acid contribute to pSS development, respectively or synergically. These results reveal the potential application of Janus kinase inhibitors for treatment of pSS, which may fundamentally improve the quality of life and prognosis of patients with pSS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2542-5641
0366-6999
2542-5641
DOI:10.1097/CM9.0000000000002539